Vascular Biogenics Ltd. (VBLT)’s Stock Is Sell After Making Yearly Low

March 14, 2018 - By Peter Erickson

The stock of Vascular Biogenics Ltd. (NASDAQ:VBLT) hit a new 52-week low and has $2.26 target or 3.00 % below today’s $2.33 share price. The 9 months bearish chart indicates high risk for the $69.11 million company. The 1-year low was reported on Mar, 14 by If the $2.26 price target is reached, the company will be worth $2.07 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 4.12% or $0.1 during the last trading session, reaching $2.33. About 346,665 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has risen 78.91% since March 14, 2017 and is uptrending. It has outperformed by 62.21% the S&P500.

Analysts await Vascular Biogenics Ltd. (NASDAQ:VBLT) to report earnings on March, 15 before the open. They expect $0.05 EPS, up 127.78 % or $0.23 from last year’s $-0.18 per share. VBLT’s profit will be $1.48 million for 11.65 P/E if the $0.05 EPS becomes a reality. After $-0.24 actual EPS reported by Vascular Biogenics Ltd. for the previous quarter, Wall Street now forecasts -120.83 % EPS growth.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Among 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Vascular Biogenics had 17 analyst reports since August 24, 2015 according to SRatingsIntel. As per Tuesday, August 15, the company rating was maintained by H.C. Wainwright. As per Thursday, March 8, the company rating was downgraded by H.C. Wainwright. On Monday, September 21 the stock rating was upgraded by JMP Securities to “Mkt Outperform”. The rating was initiated by H.C. Wainwright with “Buy” on Tuesday, June 28. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The firm earned “Buy” rating on Tuesday, October 3 by H.C. Wainwright. The company was downgraded on Friday, March 9 by Chardan Capital Markets. The company was downgraded on Thursday, March 8 by Piper Jaffray. JMP Securities downgraded Vascular Biogenics Ltd. (NASDAQ:VBLT) on Thursday, March 8 to “Hold” rating. Chardan Capital Markets maintained the stock with “Buy” rating in Friday, October 23 report.

More recent Vascular Biogenics Ltd. (NASDAQ:VBLT) news were published by: which released: “Vascular Biogenics Stock May Shoot Up On The Back Of Upcoming Catalysts” on October 30, 2017. Also published the news titled: “Vascular Biogenics’ stock plummets after brain cancer treatment trial fails” on March 08, 2018.‘s news article titled: “Why Vascular Biogenics Ltd. Is Tanking Today” with publication date: November 17, 2017 was also an interesting one.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $69.11 million. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: